Quantitative optical coherence tomography angiography biomarkers in a treat-and-extend dosing regimen in neovascular age-related macular degeneration

9Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Purpose: To evaluate the association between quantitative optical coherence tomography angiography (OCT-A) parameters and clinical outcomes in treatment-naïve neovascular age-related macular degeneration (nAMD) patients treated with a treat-and-extend dosing regimen on a 12-month follow-up interval. Methods: Observational, prospective study of consecutive patients. The treatment protocol was based on a loading dose of three anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) followed by a treat-and-extend regimen. Eyes were evaluated by swept-source OCT-A at baseline, 1 month after the loading dose and at 12 months. A quantitative analysis was issued for fractal dimension (FD), lacunarity index (LAC), blood flow surface area (SA), and vessel density (VD). An association of these parameters with the anatomic response and functional responses, and IVI number at 12 months of follow-up was assessed. A level of significance α = 0.05 was considered. Results: Sixty-four patients were included, 52 of whom (81%) completed the 12-month study protocol. The median number of injections at 12 months was 7 (P25-P75: 6-12). FD and SA were reduced 1 month after the loading dose of anti-VEGF (P < 0.001). The generalized linear models using baseline FD and baseline SA achieved the best performance in discriminating a lower treatment burden (area under the curve [AUC] = 0.78; 95% confidence interval [CI]: 0.64–0.91 and AUC = 0.76; 95% CI: 0.63–0.90, respectively). Conclusions: Baseline OCT-A may provide useful biomarkers for the treatment burden in nAMD. Translational Relevance: The application of fractal dimension and automatic blood flow area algorithms to OCT-A data can distinguish patients with distinct treatment burdens in the first year of nAMD.

References Powered by Scopus

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

859Citations
N/AReaders
Get full text

Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration

712Citations
N/AReaders
Get full text

Age-Related Macular Degeneration Is the Leading Cause of Blindness...

599Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Biomarkers in early response to brolucizumab on pigment epithelium detachment associated with exudative age‐related macular degeneration

15Citations
N/AReaders
Get full text

Early Predictive Factors of Visual Loss at 1 Year in Neovascular Age-Related Macular Degeneration under Anti–Vascular Endothelial Growth Factor

9Citations
N/AReaders
Get full text

Current Status of Clinical Trials Design and Outcomes in Retinal Gene Therapy

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Cabral, D., Coscas, F., Pereira, T., Français, C., Geraldes, C., Laiginhas, R., … Souied, E. (2020). Quantitative optical coherence tomography angiography biomarkers in a treat-and-extend dosing regimen in neovascular age-related macular degeneration. Translational Vision Science and Technology, 9(3). https://doi.org/10.1167/tvst.9.3.18

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

60%

Researcher 7

35%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 17

74%

Computer Science 2

9%

Psychology 2

9%

Environmental Science 2

9%

Save time finding and organizing research with Mendeley

Sign up for free